Plain-English translation of NCT06492122 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new radioactive medicine called in men with metastatic castration-resistant prostate cancer—a type of advanced prostate cancer that no longer responds to hormone-lowering treatments. Researchers want to understand whether this medication is safe, how well it works, and how your body processes it. The trial will enroll about 50 participants.
Men with advanced prostate cancer that stops responding to standard hormonal and chemotherapy treatments have very few options left. This medication is designed to target cancer cells more directly using radioactive particles, potentially offering a new way to slow or shrink the cancer.
You likely qualify if…
You likely don't qualify if…
If accepted into the trial, you will receive intravenous infusions of the new medication at a clinic or hospital. Some participants (about 10) will also receive a separate imaging scan with a similar but different radioactive substance to help doctors understand how the treatment moves through your body. The trial is designed in two phases: first, researchers will slowly increase doses in a small group to find a safe level, and then expand to more participants at that dose. You will have regular blood tests, scans, and check-ins to monitor how you are responding and watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States